Amgen (AMGN) Work In Process (2013 - 2017)

Amgen (AMGN) posted quarterly Work In Process of $1.6 billion for Q2 2017, up 8.16% quarter-over-quarter from $1.5 billion in Q1 2017.

Amgen (AMGN) Work In Process (2013 - 2017) Analysis & Trends

Amgen's Work In Process history runs 5 years deep, the most recent figure standing at $1.6 billion for Q2 2017.

In Q2 2017, Work In Process changed N/A year-over-year to $1.6 billion; the TTM figure through Jun 2017 stood at $1.6 billion (changed N/A YoY), while the FY2016 annual figure was $1.6 billion, up 5.17% from the prior year.
Work In Process for Q2 2017 stood at $1.6 billion, up from $1.5 billion in the prior quarter.
The five-year high for Work In Process was $2.1 billion in Q4 2013, with the low at $1.3 billion in Q2 2015.
The 5-year median for Work In Process is $1.6 billion (2014), against an average of $1.6 billion.
The sharpest annual moves came in 2015 and 2016: Work In Process slipped 28.1% in 2015, then rose 5.17% in 2016.
Amgen's Work In Process stood at $2.1 billion in 2013, then fell by 24.85% to $1.6 billion in 2014, then retreated by 1.42% to $1.5 billion in 2015, then gained by 5.17% to $1.6 billion in 2016, then climbed by 0.62% to $1.6 billion in 2017.
Business Quant data shows AMGN's Work In Process at $1.6 billion in Q2 2017, $1.5 billion in Q1 2017, and $1.6 billion in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn

Download Data